At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes
20 mai 2024 07h00 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or “the Company”) AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN DEMONSTRATES SUPERIORITY IN PHASE I CLINICAL TRIAL IN OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2...
ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY
12 mars 2024 07h30 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY Companies to combine proprietary...
Arecor: Business Update
20 juil. 2023 07h00 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Strong pipeline of revenue-generating collaborations with major pharmaceutical and biotech companies with further deals anticipated...
ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING
28 avr. 2022 07h00 HE
|
Arecor Therapeutics plc
ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING Demonstrates best-in-class potential for effective...
ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS
23 mars 2022 08h00 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR GRANTED KEY U.S. PATENT PROTECTING PROPRIETARY INSULIN PRODUCTS Further strengthens the Company’s extensive patent portfolio protecting its...
BUSINESS UPDATE
20 janv. 2022 07h01 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor”, the “Company” or the “Group”) BUSINESS UPDATEMomentum continues across partnered and proprietary portfolio Cambridge, UK, 20 January 2022: Arecor Therapeutics plc...
ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITH A LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER PRODUCT
01 nov. 2021 07h00 HE
|
Arecor Therapeutics plc
Arecor Therapeutics plc(“Arecor” or the “Group”) ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITHA LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER...